Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer By Ogkologos - April 23, 2026 95 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENGOT-ov65/KEYNOTE-B96 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Cancer-Related Fatigue: What People With Cancer and Their Loved Ones Should... August 18, 2020 Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... August 14, 2023 Doctors Think Woman Has A Brain Tumor, But Then They Open... June 17, 2019 PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer October 29, 2019 Load more HOT NEWS Addressing Cancer Pain with Complementary Methods (Part 2) EMA Recommends Granting a Marketing Authorisation for Fruquintinib How to Spend Time with Friends and Family Now that COVID... EMA Recommends Extension of Therapeutic Indications for Selpercatinib
